Our results revealed that DOX-treated BCC-derived EXOs (siNC-BCC-EXOs) significantly decreased AMVC cell viability (Fig. 6h), increased LDH release (Fig. 6i), and increased the secretion of the pyroptosis markers IL-1β and IL-18 (Fig. 6j, k), whereas EXOs derived from SF3B4 knockdown BCCs (siSF3B4-BCC-EXOs) attenuated these detrimental effects. The gene discussed is IL1B; the disease is skin basal cell carcinoma.